DNA repair protein: endo-exonuclease as a new frontier in cancer therapy.
DNA repair mechanisms are essential for cellular survival in mammals. A rapid repair of DNA breaks ensures faster growth of normal cells as well as cancer cells, making DNA repair machinery, a potential therapeutic target. Although efficiency of these repair processes substantially decrease the efficacy of cancer chemotherapies that target DNA, compromised DNA repair contributes to mutagenesis and genomic instability leading to carcinogenesis. Thus, an ideal target in DNA repair mechanisms would be one that specifically kills the rapidly dividing cancer cells without further mutagenesis and does not affect normal cells. Endo-exonucleases play a pivotal role in nucleolytic processing of DNA ends in different DNA repair mechanisms especially in homologous recombination repair (HRR) which mainly repairs damaged DNA in S and G2 phases of the cell cycle in rapidly dividing cells. HRR machinery has also been implicated in cell signaling and regulatory functions in response to DNA damage that is essential for cell viability in mammalian cells where as the predominant nonhomologous end-joining pathway is constitutive. Although HRR is thought to be involved at other stages of the cell cycle, it is predominant in growing phases (S and G2) of the cell cycle. The faster growing cells are believed to carryout more HRR in replicative stages of the cell cycle where homologous DNA is available for HRR. Targeting endo-exonucleases specifically involved in HRR will make the normal cells less prone to mutagenesis, rendering the fast growing tumor cells more susceptible to DNA-damaging agents, used in cancer chemotherapy.
Montreal General Hospital/McGill University, Department of Oncology, Division of Radiation-oncology, Montreal, Quebec H3G 1A4, Canada. tchow@po-box.mcgill.ca
Terry Y-K
TY
Chow
Sibgat A
SA
Choudhury
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002453:Cell Cycle; D004249:DNA Damage; D004260:DNA Repair; D004720:Endonucleases / Q000378:metabolism*; D005092:Exonucleases / Q000378:metabolism*; D005544:Forecasting; D042822:Genomic Instability; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D034741:RNA, Small Interfering / Q000737:chemistry / Q000378:metabolism; D011995:Recombination, Genetic
D000970:Antineoplastic Agents; D034741:RNA, Small Interfering; D004720:Endonucleases; D005092:Exonucleases; C020104:endoexonuclease